Safety and efficacy of faecal microbiota transplantation in patients with acute uncomplicated diverticulitis: study protocol for a randomised placebo-controlled trial

被引:0
|
作者
Thorndal, Camilla [1 ]
Kragsnaes, Maja Skov [2 ,3 ]
Nilsson, Anna Christine [4 ]
Holm, Dorte Kinggaard [4 ]
Christensen, Rene dePont [5 ]
Ellingsen, Torkell [2 ,3 ]
Kjeldsen, Jens [2 ,6 ]
Bjorsum-Meyer, Thomas [1 ]
机构
[1] Odense Univ Hosp, Dept Surg, Baagoes Alle 15, DK-5000 Odense, Denmark
[2] Univ Southern Denmark, Dept Clin Res, Odense, Denmark
[3] Odense Univ Hosp, Dept Rheumatol, Odense, Denmark
[4] Odense Univ Hosp, Dept Clin Immunol, Odense, Denmark
[5] Univ Southern Denmark, Dept Publ Hlth, Res Unit Gen Practice, Copenhagen, Denmark
[6] Odense Univ Hosp, Dept Med Gastrointestinal Dis, Odense, Denmark
关键词
acute uncomplicated diverticulitis; faecal microbiota transplantation; placebo; randomised controlled trial; CLOSTRIDIUM-DIFFICILE INFECTION; GUT MICROBIOTA; MEDICAL-MANAGEMENT; MOLECULAR ANALYSIS; DISEASE; RECURRENT; RISK; HOSPITALIZATION; METAANALYSIS; GUIDELINES;
D O I
10.1177/17562848241309868
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Little is known about the involvement of gut microbiota in the disease course of diverticulitis and the potential benefits of manipulating the gut milieu. We propose to conduct a randomised placebo-controlled feasibility trial of faecal microbiota transplantation (FMT) given as capsules to patients with acute uncomplicated diverticulitis.Objectives: The objective is primarily to investigate the feasibility of clinical safety, explore efficacy associated with FMT in this patient population, and examine changes in patient-reported quality of life and the composition and function of the gut microbiota.Design: Study protocol for a randomised placebo-controlled trial.Methods and analysis: Participants with acute, uncomplicated diverticulitis, as confirmed by computed tomography (CT) scan, will be recruited from Odense University Hospital (Denmark) and randomly assigned to either the intervention group or the control group. The intervention group will consist of 20 patients who receive encapsulated FMT. The control group will also consist of 20 patients, receiving placebo capsules. Primary safety endpoint: Patient safety is monitored by (a) the number of re-admissions and (b) the number of adverse events within 3 months of FMT/placebo; Primary efficacy endpoint: Reduction in the proportion of patients treated with antibiotics within 3 months following FMT/placebo; Secondary outcome: Change from baseline to 3 months in the GI-QLI questionnaire. Results will be analysed using an intention-to-treat approach. Adverse events or unintended consequences will be reported.Ethics and discussion: This is the first study to investigate the safety and efficacy of FMT in patients with acute uncomplicated diverticulitis. The project has the potential to broaden the knowledge and literature on the role of the intestinal microbiota in diverticulitis, and we believe it will elevate our understanding of cause and effect.Trial registration: Informed consent is obtained from all participants. The study is approved by the regional ethics committee (ref. S-20230023) and the Danish Data Protection Agency (ref. 24/2435). The trial was registered on clinicaltrials.gov (NCT06254625) on 10th February 2024.
引用
收藏
页数:16
相关论文
共 50 条
  • [31] Metformin treatment for patients with hand osteoarthritis: protocol for the multicentre, randomised, placebo-controlled METRO trial
    Madsen, Kasper Staberg
    Henriksen, Marius
    Dossing, Anna
    Poulsen, Asbjorn S.
    Oscar, Rasmus
    Kragstrup, Tue
    Ellegaard, Karen
    Knop, Filip K.
    Boesen, Mikael
    Hunter, David J.
    Christensen, Robin
    Bliddal, Henning
    BMJ OPEN, 2025, 15 (03):
  • [32] Efficacy of fecal microbiota transplantation in patients with Parkinson's disease: clinical trial results from a randomized, placebo-controlled design
    Cheng, Yi
    Tan, Guohua
    Zhu, Qihui
    Wang, Chun
    Ruan, Guangcong
    Ying, Senhong
    Qie, Jinlong
    Hu, Xiaofei
    Xiao, Zhifeng
    Xu, Fenghua
    Chen, Lu
    Chen, Minjia
    Pei, Yang
    Zhang, Hao
    Tian, Yuting
    Chen, Dongfeng
    Liu, Xingyin
    Huang, Heqing
    Wei, Yanling
    GUT MICROBES, 2023, 15 (02)
  • [33] A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial
    Rilinger, Jonathan
    Kern, Winfried V.
    Duerschmied, Daniel
    Supady, Alexander
    Bode, Christoph
    Staudacher, Dawid L.
    Wengenmayer, Tobias
    TRIALS, 2020, 21 (01)
  • [34] A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial
    Jonathan Rilinger
    Winfried V. Kern
    Daniel Duerschmied
    Alexander Supady
    Christoph Bode
    Dawid L. Staudacher
    Tobias Wengenmayer
    Trials, 21
  • [35] A small population, randomised, placebo-controlled trial to determine the efficacy of anakinra in the treatment of pustular psoriasis: study protocol for the APRICOT trial
    Cornelius, Victoria
    Wilson, Rosemary
    Cro, Suzie
    Barker, Jonathan
    Burden, David
    Griffiths, Christopher E. M.
    Lachmann, Helen
    McAteer, Helen
    Reynolds, Nick
    Pink, Andrew
    Warren, Richard B.
    Capon, Francesca
    Smith, Catherine
    TRIALS, 2018, 19
  • [36] A small population, randomised, placebo-controlled trial to determine the efficacy of anakinra in the treatment of pustular psoriasis: study protocol for the APRICOT trial
    Victoria Cornelius
    Rosemary Wilson
    Suzie Cro
    Jonathan Barker
    David Burden
    Christopher E. M. Griffiths
    Helen Lachmann
    Helen McAteer
    Nick Reynolds
    Andrew Pink
    Richard B. Warren
    Francesca Capon
    Catherine Smith
    Trials, 19
  • [37] Protocol for faecal microbiota transplantation in ulcerative colitis (FMTUC): a randomised feasibility study
    Jitsumura, Maki
    Cunningham, Andrew Laurence
    Hitchings, Matthew David
    Islam, Saiful
    Davies, Angharad P.
    Row, Paula E.
    Riddell, Andrew D.
    Kinross, James
    Wilkinson, Tom S.
    Jenkins, G. J.
    Williams, John G.
    Harris, Dean Anthony
    BMJ OPEN, 2018, 8 (10):
  • [38] Sertraline for anxiety in adults with a diagnosis of autism (STRATA): study protocol for a pragmatic, multicentre, double-blind, placebo-controlled randomised controlled trial
    Rai, Dheeraj
    Webb, Doug
    Lewis, Amanda
    Cotton, Leonora
    Norris, Jade Eloise
    Alexander, Regi
    Baldwin, David S.
    Brugha, Traolach
    Cochrane, Madeleine
    Del Piccolo, Maria Chiara
    Glasson, Emma J.
    Hatch, Katherine K.
    Kessler, David
    Langdon, Peter E.
    Leonard, Helen
    Macneill, Stephanie J.
    Mills, Nicola
    Morales, Maximiliano Vazquez
    Morgan, Zoe
    Mukherjee, Raja
    Realpe, Alba X.
    Russell, Ailsa
    Starkstein, Sergio
    Taylor, Jodi
    Turner, Nicholas
    Thorn, Joanna
    Welch, Jack
    Douglas, Sarah
    Hale, Peter
    O'Brien, Sarah
    Walker, Amy
    Wiles, Nicola
    TRIALS, 2024, 25 (01)
  • [39] Study protocol for the MEXiletine hydrochloride administration trial: a placebo-controlled, randomised, double-blind, multicentre, crossover study of its efficacy and safety in spinal and bulbar muscular atrophy (MEXPRESS)
    Yamada, Shinichiro
    Hashizume, Atsushi
    Hijikata, Yasuhiro
    Inagaki, Tomonori
    Ito, Daisuke
    Kinoshita, Fumie
    Nakatochi, Masahiro
    Kobayashi, Yumiko
    Hirakawa, Akihiro
    Nakamura, Tomohiko
    Katsuno, Masahisa
    BMJ OPEN, 2018, 8 (09):
  • [40] The effect of probiotics on faecal microbiota and genotoxic activity of faecal water in patients with atopic dermatitis: A randomized, placebo-controlled study
    Roessler, A.
    Forssten, S. D.
    Glei, M.
    Ouwehand, A. C.
    Jahreis, G.
    CLINICAL NUTRITION, 2012, 31 (01) : 22 - 29